Non-responders to hormone replacement therapy for the prevention of postmenopausal bone loss: do they exist?
- PMID: 8148570
- DOI: 10.1007/BF02352259
Non-responders to hormone replacement therapy for the prevention of postmenopausal bone loss: do they exist?
Abstract
Hormone replacement therapy (HRT) prevents postmenopausal bone loss, but the prevalence of non-responders in healthy early postmenopausal women is not known. In order to study this, we reviewed data from three published studies, each carried out in a randomized, placebo-controlled, longitudinal design over 2 year, that used seven hormone replacement therapies. Bone mineral content (BMC) was measured in the distal forearm by single photon absorptiometry. A mathematical model for elimination of measurement errors was applied to published BMC data. After this correction, we found that only 1.2% of early healthy postmenopausal women who are receiving HRT in conventional doses will lose more than 1% of forearm BMC per year. In conclusion, most, if not all, healthy early postmenopausal women who might need HRT against loss of bone will respond positively in forearm BMC to such therapy.
Similar articles
-
Effect of 10 years' hormone replacement therapy on bone mineral content in postmenopausal women.Bone. 1996 Nov;19(5 Suppl):191S-193S. doi: 10.1016/s8756-3282(96)90164-7. Bone. 1996. PMID: 8922661 Clinical Trial.
-
Peripheral quantitative computed tomography (pQCT) is useful for monitoring bone mineral density of the patients who receive hormone replacement therapy.Maturitas. 2007 Apr 20;56(4):343-9. doi: 10.1016/j.maturitas.2006.08.006. Epub 2006 Sep 28. Maturitas. 2007. PMID: 17010541 Clinical Trial.
-
[Postmenopausal hormonal treatment: conventional hormone replacement therapy or tibolone? Effects on bone].J Gynecol Obstet Biol Reprod (Paris). 2002 Oct;31(6):541-9. J Gynecol Obstet Biol Reprod (Paris). 2002. PMID: 12407324 Review. French.
-
Effects of hormone replacement therapy on bone mineral density in postmenopausal women with primary hyperparathyroidism: four-year follow-up and comparison with healthy postmenopausal women.Arch Intern Med. 2000 Jul 24;160(14):2161-6. doi: 10.1001/archinte.160.14.2161. Arch Intern Med. 2000. PMID: 10904459 Clinical Trial.
-
Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women.Endocr Rev. 2002 Aug;23(4):529-39. doi: 10.1210/er.2001-5002. Endocr Rev. 2002. PMID: 12202468 Review.
Cited by
-
Predicting the effects of estrogen replacement therapy on lumbar bone mineral density in oophorectomized women: analysis of a 10-year longitudinal study.Osteoporos Int. 2003 Nov;14(11):905-12. doi: 10.1007/s00198-003-1447-7. Epub 2003 Oct 8. Osteoporos Int. 2003. PMID: 14534773
-
Combination of intermittent cyclical etidronate and hormone replacement therapy for postmenopausal non-responders to estrogen.Clin Drug Investig. 2002;22(2):111-7. doi: 10.2165/00044011-200222020-00005. Clin Drug Investig. 2002. PMID: 23315398
-
A risk-benefit assessment of alendronate in the treatment of involutional osteoporosis.Drug Saf. 1998 Aug;19(2):141-54. doi: 10.2165/00002018-199819020-00005. Drug Saf. 1998. PMID: 9704250 Review.
-
Association of estrogen receptor alpha gene microsatellite polymorphism with annual changes in bone mineral density in Korean women with hormone replacement therapy.J Bone Miner Metab. 2005;23(5):395-400. doi: 10.1007/s00774-005-0619-2. J Bone Miner Metab. 2005. PMID: 16133690
-
Biochemical markers of bone turnover to monitor the bone response to postmenopausal hormone replacement therapy.Osteoporos Int. 1995;5(4):276-80. doi: 10.1007/BF01774018. Osteoporos Int. 1995. PMID: 7492867 Clinical Trial.
References
MeSH terms
LinkOut - more resources
Full Text Sources